drugset / Trial / NCT05325645
Trial of Brexpiprazole Once-weekly (QW) Formulation in Patients With Acute Schizophrenia
Phase 3
Recruiting
450 enrolled
Otsuka Pharmaceutical Co., Ltd.
Otsuka Pharmaceutical Development & Commercialization, Inc. · collab
RandomizedParallel-groupQuadruple-blindTreatment
Summary
Confirm the efficacy of the brexpiprazole QW formulation versus placebo for acute symptoms of schizophrenia
Timeline
- Start
- 2022-07-21
- Primary completion
- 2027-09
- Completion
- 2027-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Brexpiprazole | Small molecule | 48 mg | Oral |